{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:01:59Z","timestamp":1775026919621,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism Open"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.metop.2021.100096","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T23:58:08Z","timestamp":1621900688000},"page":"100096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic"],"prefix":"10.1016","volume":"10","author":[{"given":"Natalia G.","family":"Vallianou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tsilingiris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos Socrates","family":"Christodoulatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0399rene","family":"Karampela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metop.2021.100096_bib1","unstructured":"reportWHO Report. Coronavirus disease (COVID-19) pandemic. (Assessed on May 15, 2021)."},{"key":"10.1016\/j.metop.2021.100096_bib2","doi-asserted-by":"crossref","first-page":"154260","DOI":"10.1016\/j.metabol.2020.154260","article-title":"Commentary: could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?","volume":"108","author":"Dalamaga","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metop.2021.100096_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154282","article-title":"Commentary: phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19","volume":"109","author":"Dalamaga","year":"2020","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.metop.2021.100096_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2020.06.004","article-title":"Could respiratory fluoroquinolones, levofloxacin and moxifloxacin prove to be beneficial as an adjunct treatment in COVID-19?","volume":"51","author":"Karampela","year":"2020","journal-title":"Arch Med Res"},{"key":"10.1016\/j.metop.2021.100096_bib5","doi-asserted-by":"crossref","first-page":"100066","DOI":"10.1016\/j.metop.2020.100066","article-title":"The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19","volume":"8","author":"Kritis","year":"2020","journal-title":"Metabolism Open"},{"key":"10.1016\/j.metop.2021.100096_bib6","article-title":"Diabetes mellitus and SARS-CoV-2 infection: pathophysiologic mechanisms and implications in management","author":"Vallianou","year":"2020","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.metop.2021.100096_bib7","first-page":"1","article-title":"Understanding the Co-epidemic of obesity and COVID-19: current evidence, comparison with previous epidemics, mechanisms, and preventive and therapeutic perspectives","author":"Dalamaga","year":"2021","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.metop.2021.100096_bib8","series-title":"Coronavirus disease 2019 (COVID-2019) management in hospitalized adults","year":"2021"},{"key":"10.1016\/j.metop.2021.100096_bib9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"ACTT-1 study group members. Remdesivir for the treatment of covid-19-final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2021.100096_bib10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.metop.2021.100096_bib11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2021.100096_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00062-X","article-title":"The role of antirheumatics in patients with COVID-19","author":"Nissen","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.metop.2021.100096_bib13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized patients with COVID-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.metop.2021.100096_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci Adv"},{"issue":"16","key":"10.1016\/j.metop.2021.100096_bib15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.metop.2021.100096_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2021.100096_bib17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2021.100096_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.metop.2021.100096_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"16","key":"10.1016\/j.metop.2021.100096_bib20","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"INSPIRATION Investigators","year":"2021","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.metop.2021.100096_bib21","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1001\/jama.2021.4295","article-title":"Finding the optimal thromboprophylaxis dose in patients with COVID-19","volume":"325","author":"Al Samkari","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.metop.2021.100096_bib22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","article-title":"Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert Panel report","volume":"158","author":"Moores","year":"2020","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.metop.2021.100096_bib23","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/bloodadvances.2020003763","article-title":"American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19","volume":"5","author":"Cuker","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.metop.2021.100096_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","article-title":"Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY). A randomized, controlled, open-label platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metop.2021.100096_bib25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(21)00461-X","article-title":"Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomized, controlled, open-label adaptive platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metop.2021.100096_bib26","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"78","author":"Caly","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.metop.2021.100096_bib27","doi-asserted-by":"crossref","first-page":"100720","DOI":"10.1016\/j.eclinm.2020.100720","article-title":"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial","volume":"32","author":"Chaccour","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"14","key":"10.1016\/j.metop.2021.100096_bib28","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial","volume":"325","author":"Eduardo L\u00f3pez-Medina","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.metop.2021.100096_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12879-021-06104-9","article-title":"Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients","volume":"21","author":"Okumu\u015f","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.metop.2021.100096_bib30","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1128\/AAC.48.7.2693-2696.2004","article-title":"Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide","volume":"48","author":"Wu","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.metop.2021.100096_bib31","doi-asserted-by":"crossref","first-page":"173748","DOI":"10.1016\/j.ejphar.2020.173748","article-title":"A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19","volume":"891","author":"Lokhande","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metop.2021.100096_bib32","doi-asserted-by":"crossref","first-page":"2003725","DOI":"10.1183\/13993003.03725-2020","article-title":"Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial","author":"Rocco","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.metop.2021.100096_bib33","article-title":"SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma","author":"Andreano","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.metop.2021.100096_bib34","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/bjh.16981","article-title":"Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery","volume":"190","author":"Clark","year":"2020","journal-title":"Br J Haematol"},{"issue":"6534","key":"10.1016\/j.metop.2021.100096_bib40","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1126\/science.371.6534.1092","article-title":"A call to arms","volume":"371","author":"Service","year":"2021","journal-title":"Science"},{"issue":"6534","key":"10.1016\/j.metop.2021.100096_bib41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.abh3996","article-title":"Covid-19 lessons for research","volume":"371","author":"Collins","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.metop.2021.100096_bib42","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.abe0075","article-title":"De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2","volume":"370","author":"Linsky","year":"2020","journal-title":"Science"},{"issue":"7850","key":"10.1016\/j.metop.2021.100096_bib43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"571","author":"Wahl","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.metop.2021.100096_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"issue":"16","key":"10.1016\/j.metop.2021.100096_bib46","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1056\/NEJMcibr2101205","article-title":"Preparing for the future-Nanobodies for COVID-19?","volume":"84","author":"Sasisekharan","year":"2021","journal-title":"N Engl J Med"},{"issue":"6530","key":"10.1016\/j.metop.2021.100096_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"}],"container-title":["Metabolism Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936821000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936821000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:55:24Z","timestamp":1762905324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589936821000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":41,"alternative-id":["S2589936821000207"],"URL":"https:\/\/doi.org\/10.1016\/j.metop.2021.100096","relation":{},"ISSN":["2589-9368"],"issn-type":[{"value":"2589-9368","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic","name":"articletitle","label":"Article Title"},{"value":"Metabolism Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metop.2021.100096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100096"}}